1.The association of rectal equivalent dose in 2 Gy fractions (EQD2) to late rectal toxicity in locally advanced cervical cancer patients who were evaluated by rectosigmoidoscopy in Faculty of Medicine, Chiang Mai University.
Ekkasit THARAVICHTIKUL ; Pooriwat MEUNGWONG ; Taned CHITAPANARUX ; Somvilai CHAKRABANDHU ; Pitchayaponne KLUNKLIN ; Wimrak ONCHAN ; Somsak WANWILAIRAT ; Patrinee TRAISATHIT ; Razvan GALALAE ; Imjai CHITAPANARUX
Radiation Oncology Journal 2014;32(2):57-62
PURPOSE: To evaluate association between equivalent dose in 2 Gy (EQD2) to rectal point dose and gastrointestinal toxicity from whole pelvic radiotherapy (WPRT) and intracavitary brachytherapy (ICBT) in cervical cancer patients who were evaluated by rectosigmoidoscopy in Faculty of Medicine, Chiang Mai University. MATERIALS AND METHODS: Retrospective study was designed for the patients with locally advanced cervical cancer, treated by radical radiotherapy from 2004 to 2009 and were evaluated by rectosigmoidoscopy. The cumulative doses of WPRT and ICBT to the maximally rectal point were calculated to the EQD2 and evaluated the association of toxicities. RESULTS: Thirty-nine patients were evaluated for late rectal toxicity. The mean cumulative dose in term of EQD2 to rectum was 64.2 Gy. Grade 1 toxicities were the most common findings. According to endoscopic exam, the most common toxicities were congested mucosa (36 patients) and telangiectasia (32 patients). In evaluation between rectal dose in EQD2 and toxicities, no association of cumulative rectal dose to rectal toxicity, except the association of cumulative rectal dose in EQD2 >65 Gy to late effects of normal tissue (LENT-SOMA) scale > or = grade 2 (p = 0.022; odds ratio, 5.312; 95% confidence interval, 1.269-22.244). CONCLUSION: The cumulative rectal dose in EQD2 >65 Gy have association with > or = grade 2 LENT-SOMA scale.
Brachytherapy
;
Estrogens, Conjugated (USP)
;
Humans
;
Mucous Membrane
;
Odds Ratio
;
Radiotherapy
;
Rectum
;
Retrospective Studies
;
Telangiectasis
;
Uterine Cervical Neoplasms*
2.Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial
Siripa PUASRIPUN ; Nithi THINRUNGROJ ; Kanokwan PINYOPORNPANISH ; Phuripong KIJDAMRONGTHUM ; Apinya LEERAPUN ; Taned CHITAPANARUX ; Satawat THONGSAWAT ;
Journal of Neurogastroenterology and Motility 2020;26(2):259-266
Background/Aims:
The treatment of refractory functional dyspepsia (FD) is a challenge. Clidinium/chlordiazepoxide is a combination of antispasmodic and anxiolytic drugs that has been used as an adjunct treatment for FD in clinical practice with limited supporting evidence of efficacy. The aim of the study is to assess the efficacy and safety of clidinium/chlordiazepoxide as an adjunct treatment to a proton pump inhibitor (PPI) in refractory dyspepsia.
Methods:
We performed a study of patients who met the Rome IV criteria for FD who failed to respond to PPIs. Patients were randomly assigned to groups that received clidinium/chlordiazepoxide or placebo as an add-on treatment to PPI for 4 weeks. The primary outcome was the rate of responders, which was defined as a > 50% reduction in dyspepsia symptom score after 4 weeks of treatment. The secondary outcomes were an improvement in the quality of life and the safety profile.
Results:
Between March 2017 and February 2018, 78 patients were enrolled. The rates of responders in the clidinium/chlordiazepoxide group and placebo groups were 41.03 % and 5.13% at week 4 (P < 0.001). The clidinium/chlordiazepoxide group also showed significant improvement in overall quality of life over placebo. However, the clidinium/chlordiazepoxide group had more frequent drowsiness than the placebo group (30.27% vs 6.52%, P = 0.034). There were no major adverse events in either group.
Conclusions
Clidinium/chlordiazepoxide significantly improved dyspeptic symptoms and quality of life. This combination may be used as an add-on therapy in FD patients without major adverse events.